Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly’s Hopes For Tabalumab Now Rest In Lupus, Myeloma Settings

This article was originally published in The Pink Sheet Daily

Executive Summary

The company terminates all late-stage development of the anti-B cell antibody in rheumatoid arthritis due to lack of efficacy. Ongoing studies in lupus and multiple myeloma are expected to begin reporting in 2014.

You may also be interested in...



Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III

After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.

Another Blow For Lupus As Lilly’s Tabalumab Fails In Phase III

After Lilly’s monoclonal antibody fails to prove efficacy in two Phase III trials, Lupus Foundation of America pleads with FDA to “allow innovative trial design” for the disease.

Lilly Puts Faith In Late-Stage Assets In Hopes Of Profit Growth In 2014

Lilly is making major bets on the oncology and diabetes drugs in its late-stage pipeline in hopes that these assets will fill the hole left by Zyprexa, and soon Cymbalta.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel